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A B S T R A C T
Assessment of cell free DNA (cfDNA) and RNA (cfRNA), circulating tumor cells (CTC) and extracellular vesicles
(EV) in blood or other bodily fluids can enable early cancer detection, tumor dynamics assessment, minimal
residual disease detection and therapy monitoring. However, few liquid biopsy tests progress towards clinical
application because results are often discordant and challenging to reproduce. Reproducibility can be enhanced
by the development and implementation of standard operating procedures and reference materials to identify
and correct for pre-analytical variables. In this review we elaborate on the technological considerations, pre-
analytical variables and the use and availability of reference materials for the assessment of liquid biopsy targets
in blood and highlight initiatives towards the standardization of liquid biopsy testing.
1. Introduction
Cancer is a genetic disease arising from molecular alterations in
genes involved in cell survival, growth, proliferation and differentiation
making cells escape the regulatory cell cycle and form their own eco-
system (tumor) that can intervene with the physiology of organs, re-
sulting in organ failure and death if not treated properly (Hanahan and
Weinberg, 2011). Cancer can be treated by general cell death-inducing
agents, which are commonly accompanied with severe side effects,
reducing the patients’ comfort of life. Targeted therapies intervene with
molecular pathways triggered in cancer cells by genetic alterations
(DeVita and Chu, 2008; Schirrmacher, 2019). Currently, the genetic
characterization of tumors to obtain information for therapy selection
and prognosis prediction is based on tissue biopsies of the primary
tumor itself or metastases. However, tumors are a heterogeneous ag-
glomeration of cell subpopulations each carrying a distinct set of mo-
lecular alterations. Additionally, different metastatic lesions at different
locations in the body can have a different molecular profile. This can
result in the procurement of therapy resistance, since only a fraction of
the tumor or metastatic sites will be targeted, while other subpopula-
tions, carrying other mutations, can thrive and advance cancer pro-
gression (Dagogo-Jack and Shaw, 2018; McGranahan and Swanton,
2017). To cope with this heterogeneity, scientists took advantage of the
rapid turnover of cancer cells resulting in an increased release of cancer
associated materials in their extracellular environment. Biomarkers
contain relevant information concerning normal or abnormal physio-
logical processes at the single cell level. Biomarkers originating from
tumors (cancer biomarkers), including circulating tumor cells (CTC),
proteins, cell free DNA (cfDNA) and RNA (cfRNA) and extracellular
vesicles (EV), can represent the molecular status of the heterogeneous
tumor or metastases since these materials are released from different
sites in the tumor or metastatic lesions (Giulia et al., 2017; Murtaza
et al., 2015). Biomarkers can be released directly into bodily fluids or
indirectly due to disrupted tissues. The assessment of biomarkers in
biological fluids, termed “liquid biopsy”, has gained increasing interest,
especially for cancer, because of the relative ease of obtaining genetic
information without the need of performing invasive surgery. Besides
non-invasive sampling, liquid biopsies bring forward new possibilities
for cancer diagnosis and care: treatment response of a certain therapy
can be easily monitored (Annala et al., 2018; Murtaza et al., 2015;
Pantel and Alix-Panabières, 2019) and screening of population groups
at risk by simple blood sampling could increase the early detection of
cancer and hereby increase the survival rate of patients (Babayan and
Pantel, 2018; Cohen et al., 2018). Cancer biomarkers can be sampled
from bodily fluids such as blood, urine, saliva, cerebrospinal fluid, stool
and lavage fluids. In this review we will focus on blood-based liquid
biopsies.
Although research on circulating cancer biomarkers has resulted in
a plethora of possible targets, little progress has been made towards the
clinical application of liquid biopsy tests because of the lack of clinical
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validity and utility (Watts, 2018). In order to achieve clinical validity
and utility of liquid biopsy tests, its analytical validity must be assessed,
followed by prospective studies using the protocols which resulted in
analytical validity. Analytical validity includes the accuracy, sensi-
tivity, specificity and robustness of the liquid biopsy test and is de-
pendent on pre-analytical variables and protocols used for sample
preparation and biomarker detection (Merker et al., 2018). Pre-analy-
tical variables are factors without direct disease association that impact
the integrity of the bodily fluid or biomarker present in that bodily
fluid, or influence results during analysis and can be of a technical,
biological or environmental origin. The impact of pre-analytical vari-
ables is dependent on the biomarker and bodily fluid studied and
should be thoroughly assessed for each newly developed liquid biopsy
test (Agrawal et al., 2018; Ellervik and Vaught, 2015). Standard oper-
ating procedures (SOP) for the complete workflow of liquid biopsy tests
are crucial to advance their clinical implementation (Freedman and
Inglese, 2014; Khleif et al., 2010; Merker et al., 2018). For the assess-
ment of analytical validity and the influence of pre-analytical variables
as well as for the optimization of SOP, reference materials with known
properties are invaluable. Reference materials (see box 1), can further
be used to detect experimental failure, to calibrate and assess the lower
limit of detection (LOD) of measurement methods, and to assist in
biomarker quantitation.
Here, we review the technical considerations, pre-analytical vari-
ables and reference materials of the most commonly studied targets for
the development of liquid biopsy tests for cancer, including cfDNA,
CTC, EV and cfRNA.
2. The assessment of cfDNA in liquid biopsies
The presence of fragmented DNA in the non-cellular component of
blood, also termed cell free DNA (cfDNA), was first described in 1948
(Mandel and Metais, 1948). The importance of cfDNA was only re-
cognized in 1994 when a mutated RAS gene fragment was detected in
the blood plasma of pancreatic cancer patients (Sorenson et al., 1994).
cfDNA is thought to be released from cells during apoptosis and ne-
crosis, and possibly also through active secretion (Stroun et al., 2001;
Thakur et al., 2014). Enzymatic cleavage of DNA during apoptosis
results in the formation of DNA fragments of on average 166 bp, cor-
responding to DNA wrapped around a single nucleosome. Larger frag-
ments starting from 320 bp, the length of DNA wrapped around two
nucleosomes, up to>1000 bp are released from phagocytotic or ne-
crotic cells (Lo et al., 2010; Thierry et al., 2010). Concentrations of
cfDNA in blood plasma have been reported to range from 1.8 to 44 ng/
mL with a half-life shorter than 2,5 h (Fleischhacker and Schmidt, 2007;
Sorenson et al., 1994; Tie et al., 2015). The hematopoietic system,
particularly the white blood cells, is the predominant source of cfDNA
(Schwarzenbach et al., 2011; Snyder et al., 2016). cfDNA that is re-
leased from cancer cells, is also referred to as circulating tumor DNA
(ctDNA). In cancer patients, shorter ctDNA fragments compared to
normal cfDNA fragments in the range of 90–150 bp are detected in
blood plasma (Cristiano et al., 2019; Mouliere et al., 2018). The con-
centration of ctDNA in blood plasma varies among cancer patients de-
pending on type, location and stage of cancer and is frequently low
(Bettegowda et al., 2014).
The detection of somatic mutations, commonly single base-pair al-
terations, copy number variations (CNV) or chromosomal rearrange-
ments in ctDNA shows promise for early cancer diagnosis, tumor dy-
namics assessment, minimal residual disease (MRD) detection and
therapy monitoring. Mutations identified in ctDNA extracted from
blood plasma and in matched tumor tissue of cancer patients show a
high concordance rate, encouraging routine implementation of ctDNA
testing as an adjunct to tumor testing (Rothwell et al., 2019). Detection
of cancer-specific mutations in ctDNA following resection of breast and
colorectal tumors has been shown to identify patients destined to re-
lapse post-operatively in advance of established clinical parameters
(Beaver et al., 2014; Garcia-Murillas et al., 2015; Tie et al., 2016).
ctDNA also carries tissue and cancer specific epigenetic aberrations and
methylation profiles of tumor tissue highly correlate with those from
ctDNA (Xu et al., 2017). In 2016 the US Food and Drug Administration
(FDA) approved the first two blood-based assays (cobas EGFR Mutation
Test v2, Roche Molecular Systems and Epi proColon, Epigenomics) for
the detection of respectively mutations in the EGFR gene in non-small
cell lung cancer and methylated SEPTIN9 gene in colon cancer.
Box 1
Reference materials for liquid biopsies
A reference material, according to ISO guide 30:2015, is “a material, sufficiently homogeneous and stable with respect to one or more specified
properties, which has been established to be fit for its intended use in a measurement process”. Important notes that accompany this definition
are that: 1) the term “reference material” is a generic term; 2) the properties can be quantitative or qualitative; 3) the uses can include the
calibration of a measurement system, assessment of a measurement procedure, assigning values to other materials, and quality control; and 4)
it can only be used for a single purpose in a given measurement.
The generic term “reference material” can further be subdivided in: 1) certified reference materials, which are characterised by a
meteorologically valid procedure for one or more specified properties, accompanied by a certificate that provides the value of the specified
property, its associated uncertainty, and a statement of metrological traceability; 2) quality control materials, which are non-certified
reference materials often produced in-house, thus are not sufficiently characterised to provide metrological traceability; and 3) calibrants,
which should have a fixed property value with an appropriate uncertainty tolerable for calibration and metrological traceability of the
property value. In theory, a calibrant should always be a certified reference material, but in practice they often lack proper certification;
however, a certified reference material is not always a calibrant because the uncertainty stated in the certificate is not always tolerable for
calibration (Emons, 2006). Since there are very few certified reference materials available for liquid biopsy tests, in this review we will use the
terms pre-analytical reference material for materials being used for calibration, quality control and assessment of measurement methods,
and analytical reference materials for materials being used to assign values to other materials or defining the LOD of measurement methods.
The former can be used to assess pre-analytical variables and their influence on experiments, while the latter can be used for liquid biopsy
testing, by comparing its property value with that of the patient material (Fig. 1).
Commutability of a reference material implies that it behaves comparably to the actual sample undergoing the procedure and as such is a
procedure-specific characteristic, defined by the behaviour of the reference material (Vesper et al., 2007). The correct assessment of reference
material commutability is important, as biases will arise when using non-commutable reference materials, leading to inaccurate results.
A reference material can be spiked in samples (spike-in) and used to assess and mitigate technical errors between samples by functioning as
an internal quantitative or qualitative control, or can be used as a scaling factor for normalization purposes between samples. Alternatively, a
reference material can be used as an external control to compare obtained results or to assign specific property values to a sample for
diagnosis. In general, commutability is harder to achieve for a spike-in compared to an external control. Additionally, a spike-in reference
material should be distinguishable from the molecules under investigation (Hardwick et al., 2017).
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2.1. Technological considerations
Screening for clinically relevant mutations in ctDNA is challenging
because ctDNA is highly fragmented and because it is masked by a high
background of total cfDNA, resulting in allele frequencies (AF) lower
than 0.1%, especially for early stage tumors or micrometastases
(Bettegowda et al., 2014; Li et al., 2019). Although significant progress
has been made in advancing the detection and analysis of ctDNA in the
last few years, the current challenges include standardization and im-
proving current methods to reach single molecule sensitivity in com-
bination with high specificity.
Blood contains whole blood cells. During sample processing, storage
and transport, cell lysis may occur resulting in the release of genomic
DNA (gDNA) that contaminates the cfDNA fraction and potentially
leads to false negative results. There are different strategies to assess the
degree of gDNA contamination. DNA capillary electrophoresis allows to
estimate the DNA fragment sizes. Quantification of short and long se-
quences of the same gene using quantitative PCR (qPCR) enables the
analysis of the amplicon ratio long/short. To prevent gDNA con-
tamination, specialized blood tubes are available that stabilize blood
cells and prevent disruption (Johansson et al., 2019; Nikolaev et al.,
2018; Norton et al., 2013).
Different methods are commercially available to extract cfDNA from
blood plasma (Fong et al., 2009; Trigg et al., 2018). An optimal cfDNA
extraction approach should purify all cfDNA fragments to the same
extent, maximize yield and minimize the presence of PCR inhibitors.
Magnetic enrichment of cfDNA is achieved by binding with functiona-
lized magnetic beads, whereas silica column-based enrichment makes
use of the binding affinity of DNA molecules at specific buffer condi-
tions. cfDNA can also be captured by polymer mediated precipitation,
in which the cfDNA is not soluble, or by a phenol-chloroform based
extraction (Ali et al., 2017). Today, most methods are based on either
magnetic beads or silica-based membranes.
ctDNA can be detected by enrichment using PCR, digital PCR or
next generation sequencing (NGS) (Li et al., 2019). The former two are
targeted approaches based on the analysis of a single or a selection of
Fig. 1. Schematic overview showing the use of pre-analytical and analytical reference materials during liquid biopsy test development.
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clinically actionable mutations. This approach requires a priori
knowledge of the target mutation but has a high sensitivity and speci-
ficity and is fast and cost-effective. NGS-based detection relies on un-
targeted screening of the extracted cfDNA for the presence of clinically
actionable mutations. A priori knowledge of the mutation is not re-
quired for this approach but NGS introduces errors during amplifica-
tion, library preparation and sequencing, resulting in error rates of
0.1–0.5%, making it impossible to detect ctDNA with AF lower than
0.5%. Recent approaches to increase the sensitivity of NGS, such as
Safe-SeqS, CAPP-Seq and TAmSeq have succeeded and require high
level expertise or specific bioinformatic approaches (Newman et al.,
2016; Pécuchet et al., 2016; Schmitt et al., 2012). Another approach to
enhance NGS sensitivity is by increasing the bodily fluid input volume,
hereby increasing the total amount of cfDNA (Johansson et al., 2019).
Further developments to improve the detection of ctDNA with NGS-
based screening include selecting specific sizes of cfDNA fragments
prior to sequencing, assessment of the epigenetic methylome, devel-
opment of bioinformatics algorithms and improving standardization
(Cristiano et al., 2019; Mouliere et al., 2018; Xu et al., 2017; Zavridou
et al., 2018).
2.2. Pre-analytical variables
Interlaboratory variation can be induced by pre-analytical variables
such as extraction and quantification method used, storage conditions,
PCR inhibition and fragment size bias (Fleischhacker et al., 2011;
Fleischhacker and Schmidt, 2007; Khleif et al., 2010; Trigg et al., 2018;
van Dessel et al., 2017; Whale et al., 2018). To date no consensus SOP is
available to assess cfDNA in blood plasma, but research concerning the
impact of pre-analytical variables on cfDNA analysis is steadily in-
creasing (Devonshire et al., 2014; El Messaoudi et al., 2013; Johansson
et al., 2019; Merker et al., 2018; Nikolaev et al., 2018).
Plasma is preferred to serum for the extraction of cfDNA, as the
latter is contaminated with gDNA due to blood cell lysis that occurs
during clotting (Li et al., 2019; Merker et al., 2018). EDTA tubes can be
used as long as they are processed in less than 6 h at room temperature,
or 24 h when stored at 4 °C. After these time points an increase of gDNA
is observed. Alternatively, specialized tubes that prevent cell lysis can
be used (PAXgene tubes, Qiagen; BCT tubes, Streck Inc.; cfDNA col-
lection tubes, Roche Diagnostics), which allow the storage of blood
plasma up to 48 h at room temperature prior to processing (Grölz et al.,
2018; Merker et al., 2018; Nikolaev et al., 2018; van Dessel et al.,
2017). Two centrifugation steps above 800 g and longer than 10min
are preferred to one in order to avoid contamination of the plasma with
white blood cells. The centrifugation speed or temperature does not
impact cfDNA recovery (Trigg et al., 2018). Storage of processed
plasma samples at −80 °C up to one year does not degrade cfDNA.
Longer storage at −80 °C results in 30% degradation per year. Multiple
freeze thawing steps of blood plasma and freeze thawing of whole blood
is not recommended (El Messaoudi et al., 2013; Merker et al., 2018;
Sozzi et al., 2005).
A multitude of cfDNA extraction methods are available.
Comparative studies of different cfDNA extraction methods revealed
method dependent cfDNA yields, fragment lengths and detection of
target genes (Devonshire et al., 2014; Fleischhacker et al., 2011).
Awareness of pre-analytical variables and their impact is important and
requires transparent reporting to increase interlaboratory reproduci-
bility.
2.3. Reference materials for cfDNA
2.3.1. Pre-analytical reference materials
Reference materials for the assessment of pre-analytical variables in
cfDNA research should only match the physical characteristics of
cfDNA, of which the fragment size is the most important one. To assess
the performance of cfDNA extraction, synthetic or exogenous DNA
sequences of different length can be spiked in known concentrations in
blood plasma prior to extraction. By comparing the quantitative signal
after extraction with the signal of the reference material that was not
spiked, the extraction efficiency can be assessed, as well as fragment
size bias of the extraction (Whale et al., 2018). The ADH plasmid, which
shows no homology with the human genome, treated with restriction
enzymes resulting in DNA fragments of 115, 461 and 1448 bp is com-
monly used for this purpose, however other exogenous DNA sequences
can also be used. Using this fragmented plasmid, Devonshire et al.
compared different cfDNA extraction kits and observed that certain kits
extract more efficiently shorter fragments, while others are biased to-
wards larger fragments (Devonshire et al., 2014).
Spiking synthetic or exogenous DNA sequences after cfDNA ex-
traction helps to identify the presence of PCR inhibitors (Whale et al.,
2018). PCR inhibitors can be introduced during blood sample collec-
tion, cfDNA extraction or over-concentrating the extracted cfDNA. The
most commonly known PCR inhibitors are heparin, hormones and IgG,
which lower the efficiency of the PCR reaction resulting in higher Cq
values or lower read counts for qPCR or NGS respectively (Johansson
et al., 2019; Sah et al., 2013). Higher Cq values or lower read counts for
the spiked reference material compared to the pure reference material
are indicative for the presence of PCR inhibitors (Devonshire et al.,
2014; Johansson et al., 2019; Whale et al., 2018). PCR inhibition can be
resolved by either diluting or re-extracting the cfDNA.
2.3.2. Analytical reference materials
Analytical reference materials should not only match the physical
characteristics but also the biological characteristics of ctDNA. For the
detection of ctDNA, especially with NGS, one should be able to detect
and distinguish somatic mutations from germline cfDNA. It is thus
important for analytical reference materials to contain a matched
germline cfDNA background together with a minor fraction of ctDNA.
The most ideal reference material would be cfDNA from clinically va-
lidated patients. However, since cfDNA is only present in limited
amounts in bodily fluids and reference materials should have little
variation between batches, this is not practically feasible.
For the evaluation of liquid biopsy tests based on ctDNA, the LOD
should be thoroughly assessed to exclude false negative results. The
LOD can be assessed by introducing a specific mutation or alteration in
gDNA and mixing this mutated gDNA with control background gDNA at
specified AF. However, genome editing is prone to off target effects and
PCR-based mutagenesis can introduce random errors, making this a less
reliable reference material (Yang et al., 2017). A much considered ap-
proach to assess the LOD is to isolate DNA from well characterised cell
lines, mostly transformed cells from patient samples carrying clinical
variants of interest, fragment this DNA by ultrasonication and mix the
DNA fragments with isogenic control DNA at fixed concentrations to
reach pre-set AF. With these mixes, each containing ctDNA at de-
creasing concentrations, the LOD can be estimated (Denroche et al.,
2015; Harkins et al., 2016; Zhang et al., 2017). Nonetheless, ultra-
sonication results in relatively broad size distributions and damaged
DNA ends, hereby adversely affecting the commutability of the re-
ference material during isolation and analysis (Konigshofer et al., 2017;
“Seraseq ctDNA: A Breakthrough QC Technology,”; Zhang et al., 2017).
Zhang and colleagues mimicked the nucleosomal footprint of cfDNA
by treating CRISPR/Cas9 edited cells, bearing frequently occurring
genomic rearrangements, with micrococcal nuclease (MNase). The
latter is able to digest DNA between nucleosomes in vivo (Tsang and
Chan, 2017; Zhang et al., 2017). This ctDNA mimic can then be mixed
with MNase treated control DNA to achieve pre-set AF. In their pub-
lication they propose a synthetic cfDNA quality control material
(SCQCM) existing from MNase treated CRISPR/Cas9 edited and control
cells and control DNA that underwent PCR-based site directed muta-
genesis to introduce 6 frequently occurring driver mutations. They state
that this SCQCM can be used for the monitoring of false-positive and
false-negative results. A major limitation of this reference material is
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the lack of cfDNA extraction from complex bodily fluids. Also, it is
impractical to spike this reference material in blood, as it already
contains cfDNA, not matching the background of the reference mate-
rial. Ideally, a reference material should be applicable for the evalua-
tion of the complete cfDNA analysis work flow (from plasma prepara-
tion to analysis). To meet this need, NIST, in collaboration with
SeraCare, has developed cfDNA reference materials for multiple dis-
orders at pre-defined AF in a synthetic human plasma matrix
(Konigshofer et al., 2017; “Seraseq ctDNA: A Breakthrough QC Tech-
nology,”).
Such analytical reference materials are not restricted to assess the
LOD but are also applicable for the quantitative assessment of ctDNA in
patient samples. By preparing reference materials with increasing AF, a
standard curve can be constructed from which the AF of the ctDNA
sequence of interest can be deduced (Denroche et al., 2015; Hardwick
et al., 2017). This is particularly of interest for therapy response mon-
itoring and MRD assessment, where the ctDNA AF is correlated with the
tumor load.
3. The assessment of CTC in liquid biopsies
The first documented case of CTC dates back from 1869, where
Thomas Ashworth observed cells in the blood of a man, deceased due to
metastatic disease, that resembled the primary tumor cells micro-
scopically (Ashworth, 1869). During both late and early stages primary
tumors shed cells in the circulation that can seed at distant sites of the
body and form metastatic lesions (Braun et al., 2005; Massagué and
Obenauf, 2016). CTC are a rare event, with 1 CTC present for 1×106 –
1× 109 blood cells depending on the disease state (Tibbe et al., 2007).
They have a half-life of 1–2.4 h and can be distinguished from me-
senchymal blood cells by the expression of epithelial surface proteins,
such as epithelial cell adhesion molecule (EpCam) or proteins of the
cytokeratin family (CK8, CK18 and CK19), or by their epithelial mor-
phology (Alix-Panabières and Pantel, 2013; Giulia et al., 2017; Lianidou
and Markou, 2011; Meng et al., 2004; Pantel et al., 2012). However,
cancer cells in the circulation can undergo epithelial to mesenchymal
transition (EMT), losing their epithelial phenotype and surpassing the
immune system with a mesenchymal phenotype. Along this process, the
expression of cytokeratins and EpCam is lost and the morphology is
altered (Alix-Panabières et al., 2017; Yu et al., 2013). Some studies
report that these mesenchymal CTC are more prone to form metastases
(Bourcy et al., 2016; Bulfoni et al., 2016; Mego et al., 2012).
CTC can be captured from the circulation, quantified and char-
acterised to aid molecular identification of the primary tumor or me-
tastases, and therapy response monitoring (Lianidou and Pantel, 2019).
Detection of cancer-specific splice variants by assessing mRNA of CTC
identifies patients destined to develop therapy resistance (Antonarakis
et al., 2014; Armstrong et al., 2019). Patients with a higher CTC count
have a more than two fold less median overall survival compared to
patients with a lower CTC count (Cristofanilli et al., 2019). To date the
CellSearch system, which is based on enumeration, is the only CTC-
based FDA-approved test (Riethdorf et al., 2018, 2007).
3.1. Technological considerations
CTC have to be enriched from blood which already contains millions
of cells. Characterization and enumeration of CTC is typically not per-
formed on pure CTC isolates but on 3–4 log enriched CTC, aiming at the
presence of 1 CTC for 1000 blood cells or less. Since CTC follow the
Poisson distribution, the LOD is defined by the amount of blood that is
available (Tibbe et al., 2007). This is reflected by the necessity of
22.5 mL or 7.5mL of blood to detect CTC with high fidelity in early or
metastasized cancer patients respectively, making use of the CellSearch
system (Lianidou and Pantel, 2019; Riethdorf et al., 2018). This rela-
tively large amount of blood can be overcome by in vivo CTC enrich-
ment by inserting a nanodevice via a standard gauge needle in the
bloodstream of a patient for 30min, hereby increasing the chance of
effectively capturing a CTC (Alix-Panabières and Pantel, 2013;
Saucedo-Zeni et al., 2012).
CTC can be enriched from the blood via positive or negative selec-
tion based on protein expression or physical properties. Enrichment
based on protein expression, the most implemented method, makes use
of specific proteins present on the surface of CTC that are absent on the
surface of circulating blood cells in case of positive selection or the
other way around in case of negative selection. Commonly used targets
for these enrichment strategies comprise the epithelial surface protein
EpCam or blood cell specific surface proteins such as CD45. Enrichment
based on physical properties makes use of the size, density, deform-
ability or electric charges specific for CTC (Alix-Panabières and Pantel,
2014; Khoo et al., 2017; Rawal et al., 2017).
Detection, enumeration and characterization of CTC is mostly per-
formed concomitantly with the enrichment in a microfluidic device.
This can be done by using fluorescent imaging, molecular assays
(mostly PCR-based) or protein assays (detecting tumor specific proteins
released by CTC). The number and characteristics of CTC can be as-
sessed by distinguishing CTC from contaminating blood cells with
Immunocytochemistry (ICC), fluorescent in situ hybridisation (FISH) or
padlock probe assays together with DAPI staining; PCR-based methods
for molecular characterization are sensitive enough to detect CTC-as-
sociated signatures in these conditions (Alix-Panabières and Pantel,
2014; El-Heliebi et al., 2018; Lianidou and Markou, 2011).
The restricted use of epithelial cell markers for CTC enrichment
poses problems for the specificity and sensitivity of the assay. First of
all, CTC that underwent EMT lose their epithelial-specific proteins and
physical properties. This implies that they are not captured by classical
CTC isolation methods, resulting in an increase of the false negative
detection rate (Alix-Panabières et al., 2017; Yu et al., 2013). Therefore,
it should be considered to not only focus on epithelial markers, but also
on mesenchymal markers without increasing the false positive rate by
identifying blood cells as CTC. To date, there is no consensus on po-
tential mesenchymal targets that could be used, however, the use of
surface expressed vimentin could pose a solution (Satelli et al., 2015).
Furthermore, a combination of mesenchymal capturing strategies and
FISH assays for the nuclear organisation of transcription factors, like
transforming growth factor (TGF) 1-β or FOXC1, or molecular assays to
identify tumor specific alterations are also under consideration (Wu
et al., 2016; Yu et al., 2013). Another argument that could stand against
the use of EpCam to capture CTC is the fact that there are reports of
circulating epithelial cells in patients with benign diseases, which could
result in false positive results (Pantel et al., 2012). Also, different sub-
populations of CTC exist which are more prone to extravasation and
metastasis formation than others. These CTC are characterised by a
specific set of surface proteins including CD47, CD44, MET and EpCam
but also HER2, EGFR, HSPE and notch (Baccelli et al., 2013; Zhang
et al., 2013).
To obtain information about intra-patient heterogeneity, genome
analysis should be performed on individual CTC. Single cell sequencing
makes use of whole genome amplification, which is prone to systematic
errors that can result into false findings. Investment in single cell ana-
lysis methods is thus highly needed for accurate diagnosis making in the
future (Alix-Panabières and Pantel, 2014).
3.2. Pre-analytical variables
The most important, and most analysed, pre-analytical variables
that can impact downstream analysis of CTC are the type of blood
collection tube used, time between sampling and analysis and storage
temperature of whole blood. Depending on the downstream method of
analysis, pre-analytical variables may have different impacts.
Blood collection aimed at CTC analysis should be performed in
EDTA containing blood collection tubes or tubes designed for cfDNA
isolation containing a formaldehyde free preservative to ensure the
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structural stability of CTC. However, the choice of either EDTA or
preservative containing tubes can have a major impact on the obtained
results (Grölz et al., 2018). For enumeration and characterization based
on imaging, ICC, FISH or padlock probe analysis directly after blood
draw (less than 6 h) no consensus is available on which blood tube to
use (Flores et al., 2010; Luk et al., 2017). When the time to analysis is
increased, preservative containing tubes are preferred (Ilie et al., 2018).
However, caution is advised since these tubes were initially developed
for cfDNA research, where they were used to minimize gDNA con-
tamination of lysed leukocytes, hence leukocytes present in the blood
are also preserved and could interfere with the analysis (Luk et al.,
2017). For molecular characterization of CTC, through PCR-based ap-
proaches, preservative containing tubes are strongly discouraged. Even
when CTC enrichment and analysis are performed directly after sam-
pling, significantly low DNA or RNA yields were obtained, after more
than 24 h almost no nucleic acids were found when using preservative
containing tubes. Using EDTA tubes, CTC associated nucleic acids could
still be detected up to 96 h later (Luk et al., 2017; Wong et al., 2017;
Zavridou et al., 2018). If the aim is to culture CTC ex-vivo or the
generation of a xenograft model, preservatives cannot be used as these
contain fixatives that interfere with the cell cycle.
Blood samples for CTC analysis can be stored at room temperature
without significant effects up to 72 h (Apostolou et al., 2017; Grölz
et al., 2018). For molecular characterization however, one could reason
that storage at room temperature could influence RT-qPCR results as a
consequence of up- or downregulation of transcripts as an active re-
sponse to cellular stress (Benoy et al., 2006). Therefore, storage of
EDTA tube collected blood for molecular characterization of CTC could
better be performed at 4 °C. This again poses a problem for CTC en-
richment, which is mostly performed in microfluidic devices, as hy-
pothermic temperatures result in platelet activation with clotting as a
result, which could lead to failure of the microfluidic device. Wong
et al. have bypassed this problem by the addition of glycoprotein IIb/
IIIa inhibitors to EDTA blood collection tubes, which resulted in stable
live CTC isolation for up to 72 h with high quality RNA for molecular
characterization (Wong et al., 2017).
Another important variable, not a pre-analytical but an analytical
variable, which should be appreciated is inter-reader variability. Since
CTC are rare events, severely outnumbered by hematological cells,
different operators could obtain different cut-off values.
Standardization of the interpretation of CTC analysis tests, through
specialists training, is thus highly recommended (Cummings et al.,
2013).
3.3. Reference materials for CTC
3.3.1. Pre-analytical reference materials
All pre-analytical variables discussed above were assessed by using
established in vitro cultures from specific cancer types. Known con-
centrations of cancer cells, cultured in vitro, are spiked in whole blood
and subsequently the recovery is assessed under varying test conditions.
Obtained results should always be validated using patient material
because these cells are adapted for in-vitro culture and have undergone
structural and molecular changes (Lipps et al., 2013). Especially for the
assessment and validation of CTC isolation methods this poses a serious
concern. It has been observed that CTC can significantly differ from
their cell culture counter parts on the basis of size, morphology, nu-
clear:cytoplasmic ratio and fluorescence intensity after staining for
certain markers (Lazar et al., 2012; Park et al., 2014). The best possible
reference material to assess these variables correctly is by using CTC
isolated from patients, but since these cells are so rare, it is impossible
to provide sufficient material for wide spread use. This could be over-
come by the immortalization of isolated CTC for in vitro culture.
However, immortalization can impact signalling pathways and only few
attempts in long time culture of CTC have succeeded (Franken et al.,
2019; Maheswaran and Haber, 2015; Pantel and Alix-Panabières, 2015;
Yu et al., 2018).
3.3.2. Analytical reference materials
An optimal analytical reference material should be able to help
define the MRD in a patient, by assessing CTC count or the AF of altered
genes when looking at remaining CTC after therapy. Such a reference
material already exists for chronic myelogenous leukaemia and
Philadelphia chromosome-positive acute lymphoblastic leukaemia
(White et al., 2010). This reference material consists of mixtures of
freeze dried K562 (BCR-ABL positive) and HL60 (BCR-ABL negative)
cells at fixed 10%, 1%, 0.1% and 0.01% MRD, which is meant for the
calibration and certification of secondary reference materials. By using
this reference material, or secondary materials calibrated with it, clin-
icians can with high reproducibility and certainty deduce the MRD of a
patient after therapy.
A first approach of developing such an analytical reference material
was published recently. Tommasi and colleagues implemented prostate
cancer LnCap cells, carrying known mutations of the androgen receptor
(AR), in three different concentrations as a reference material to stan-
dardize RT-qPCR analysis, assess the LOD and evaluate other pre-ana-
lytical variables (Tommasi et al., 2019).
Further development of similar reference materials is hampered by
the absence of consensus on using molecular analysis of CTC as a
prognostic or predictive biomarker. Optimization of single cell analysis
methods is thus first needed before these kind of analytical reference
materials would find use in a clinical setting.
4. Assessment of extracellular vesicles in liquid biopsies
Extracellular vesicles (EV) are nanovesicles ranging from 50 to
1000 nm secreted by all cell types and consist of a lipid bilayer sur-
rounding a cargo consisting of proteins, nucleic acids and metabolites
(Kalra et al., 2016; van Niel et al., 2018). EV can bud directly from the
plasma membrane or can be released by fusion of a multivesicular body
(late endosome) with the plasma membrane, giving rise to respectively
microvesicles or exosomes. Apoptotic bodies, arising as membrane
blebs during the apoptotic process, are also categorized as EV. Each EV
subpopulation has its own route of biogenesis and can be characterised
by or share a specific set of proteins. However, up until now there is no
consensus on the classification of EV subtypes based on protein char-
acteristics (Baietti et al., 2012; Jeppesen et al., 2019; Kowal et al., 2016;
Nabhan et al., 2012; Tulkens et al., 2018; Zhang et al., 2018). EV are
involved in intercellular communication both locally and at greater
distances, making use of the blood- or lymph circulation (Maas et al.,
2017; Valadi et al., 2007; Zomer et al., 2015). Half-lives have been
reported in mice ranging from 20 to 180min and the EV concentration
in healthy individuals is approximately 1.46× 1011/mL plasma
(Geeurickx et al., 2019; Lai et al., 2014).
EV are secreted by cancer cells and can either activate or recruit
cancer or stromal cells locally or educate a premetastatic niche at a
distant location, hereby facilitating metastasis formation (Hoshino
et al., 2015; Kalluri, 2016; Peinado et al., 2012; Tkach and Théry,
2016). Recently, EV separated from different bodily fluids have been
found to contain specific mRNA, miRNA and protein content related to
the disease state for multiple cancer types. This makes them interesting
targets for liquid biopsies as they represent a fingerprint of the origi-
nating cell (Melo et al., 2015; Nawaz et al., 2014; Sadovska et al., 2015;
Tang and Wong, 2015; Zhang et al., 2015). Not only their cargo but also
their numbers in plasma can be indicative for cancer and recurrence
after therapy (Osti et al., 2019).
Research into extracellular vesicles (EV) raises hope to gain biolo-
gical insights and identify novel diagnostics and therapeutics for a wide
range of pathological conditions. However, the plethora of methods to
separate and characterize EV, the intrinsic heterogeneity of EV subtypes
and the complexity of bodily fluids block the road towards rigor in EV
research and clinical application (De Wever and Hendrix, 2019).
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4.1. Technological considerations
EV are most commonly separated from bodily fluids by differential
ultracentrifugation (dUC), size exclusion chromatography (SEC), den-
sity gradient (DG) centrifugation and immune capture targeting EV-
associated tetraspanins CD9, CD63 and CD81, but commercial pre-
cipitation methods also exist (Coumans et al., 2017a; Théry et al., 2018;
van der Pol et al., 2016). More than 1000 unique EV separation
methods have been reported in literature, each separating EV with
different specificity and efficiency (Van Deun et al., 2017, 2014). To
understand the functional significance of intercellular communication
via EV, the EV-specific proteome, transcriptome and lipidome should be
accurately defined without the presence of non-vesicular contaminants
such as abundant proteins or lipoproteins present in blood. The em-
ployment of a density gradient is up until now the only method to
discern EV from protein complexes and should be used to validate the
association of a biomarker with EV (Théry et al., 2018; Van Deun et al.,
2017). However, a density gradient cannot discern EV from high den-
sity lipoproteins abundantly present in blood and able to bind miRNA.
As such, a combination of multiple methods (size and density) can help
to obtain higher specificity (Karimi et al., 2018; Onódi et al., 2018;
Simonsen, 2017; Tulkens et al., 2018). The International Society for
Extracellular Vesicles (ISEV) has recently defined the minimal experi-
mental requirements to identify an EV-associated biomarker (Théry
et al., 2018).
Although the EV concentration in blood is increased in cancer pa-
tients (Geeurickx et al., 2019; Osti et al., 2019), the majority of circu-
lating EV is released by hematopoietic cells. Since most EV separation
methods are based on generic biophysical or biochemical properties of
EV, tumor-specific EV cannot be distinguished from hematopoietic EV.
This problem could be circumvented by direct capture and analysis in
unprocessed or partly processed bodily fluids by targeting cancer-spe-
cific membrane proteins, which should also be present in the membrane
of their respective EV (Melo et al., 2015; Zhang et al., 2019).
Sizing and quantification of EV is mostly based on their light scat-
tering properties through nanoparticle tracking analysis (NTA) and flow
cytometry (FCM), although EM or resistive pulse sensing are occa-
sionally performed for these purposes as well. Each method has its
limitations and merits, and it is important to take them into account
during analysis. Light scattering methods lack the ability to properly
distinguish vesicles from non-vesicular particles, thus these particles
could be mistakenly quantified as EV (Filipe et al., 2010; Van Deun
et al., 2014). The amount of light that is scattered by a certain particle
of a certain size is related to the refractive index, which for EV is low.
This consequently defines the LOD, which is dependent on the sensi-
tivity of the camera used by the specific method (Dragovic et al., 2011;
van der Pol et al., 2014). For this reason it is impossible to compare the
measured concentration from one method to another without the use of
a calibrator (Valkonen et al., 2017; van der Pol et al., 2014). The low
refractive index also restricts the minimum size of EV that can be as-
sessed, larger particles scatter more light with the result that smaller
vesicles are not detected or are masked by the scattering signals of
larger EV (Filipe et al., 2010). Conventional FCM lacks the sensitivity to
accurately measure EV because it was initially developed for quanti-
fying cells. This can be circumvented by hardware and software adap-
tations, but also by fluorescently labelling EV with lipid dyes and
measuring through fluorescent triggering (’t Hoen et al., 2012; van der
Pol et al., 2018; van der Vlist et al., 2012; Welsh et al., 2017). However,
caution is advised with the latter solution as it has been shown that
lipid dyes not only bind with the lipid bilayer, but also with protein
aggregates and lipoproteins (de Rond et al., 2018). Alternatively,
fluorescently labelled antibodies targeting EV-associated tetraspanins
and FCM could be used (Kormelink et al., 2015). Using this metho-
dology, results could be biased as there is a possibility that only a
subpopulation of EV is labelled. Another phenomenon that can cause
misinterpretation of results is the swarm effect, where multiple EV pass
the laser at the same time resulting in one count. This can be corrected
for by performing multiple dilutions of the same sample and re-
measuring it until a linear correlation is obtained (Kormelink et al.,
2015; van der Pol et al., 2012). EM has the advantage that the operator
can choose what is quantified, giving the possibility to not include
protein aggregates in the analysis. Recently a tool was developed to
standardize vesicle sizing and counting, making this technique more
approachable (Kotrbová et al., 2019). However, during EM samples are
centrifuged, fixed and dehydrated resulting in loss and morphological
changes of EV, again influencing the analysis (van der Pol et al., 2014).
Methods to analyse EV for biomarker discovery are dependent on the
EV-associated molecule being studied. Since EV can contain cancer cell
related RNA, DNA, proteins or lipids the analysis methods range from
RT-qPCR, NGS, proteomics and lipidomics being performed con-
comitantly with (on a microfluidic device) or after EV separation
(Coumans et al., 2017a; Gézsi et al., 2019; van der Pol et al., 2016).
4.2. Pre-analytical variables
The EV community is fully aware of the complexity of analysing EV
in bodily fluids and therefore ISEV published several position papers
concerning the above-mentioned pit falls and the influence of pre-
analytical variables (Mateescu et al., 2017; Théry et al., 2018; Witwer
et al., 2013).
When isolating EV from blood, plasma is the preferred matrix
compared to serum because platelets secrete an increasing amount of
EV during coagulation which could result up to 50% of the total amount
of EV present in serum (Coumans et al., 2017a; Gemmell and
SeftonYeo, 1993). When preparing plasma, the preferred anti-coagulant
is sodium citrate and platelets should be depleted, preferably by double
centrifugation for 15min at 2500 g. Plasma should be prepared in a
maximum time span of 2 h and can be frozen at −20 °C and −80 °C up
to one year without impact on EV size and concentration (Yuana et al.,
2015). However, when separated, EV should be frozen at −80 °C; this
and the following thawing should be performed as quickly as possible
(Jeyaram and Jay, 2018). When storing, concentrating or measuring EV
protein concentration it is also advised to consider the materials to use
as it has been noticed that some vials and cut-off membrane tend to be
more sticky to EV and that some protein concentration methods over- or
underestimate the real protein concentration (Vergauwen et al., 2017).
Important patient-associated pre-analytical factors when working with
blood are prandial status, level of exercise and inflammation, as these
are known to alter EV levels in patient plasma (György et al., 2011;
Witwer et al., 2013).
The plethora of methods and protocols can be confusing, but it is
probably unavoidable, given the diverse nature of EV and innovative
character of the EV research field (De Wever and Hendrix, 2019). To
cope with this variety of methods the scientific community needs to
increase the awareness of essential experimental parameters and needs
to report them sufficiently to make EV research transparent, so we can
understand each other's experiments and reproduce data. Specifically,
the EV-TRACK knowledgebase (http://evtrack.org/) is an online open
access resource to track and organize data on EV separation and char-
acterization and therefore to monitor the progress in the field of EV in a
standardized format. In the current set-up, a check-list of nine essential
experimental parameters to improve the transparency in the field are
identified and bundled into an EV-METRIC (Van Deun et al., 2017).
Guidance to use EV-TRACK and its EV-METRIC is previously reported
(Van Deun and Hendrix, 2017).
4.3. Reference materials for EV
Light scattering methods to detect EV require proper calibration to
ensure that the correct size and concentration is actually measured. For
these purposes polystyrene or silica beads with pre-set size and con-
centrations are often used. However the refractive indices of these
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beads are respectively 1.61 and 1.46 compared to a refractive index of
approximately 1.39 that is reported for EV (Gardiner et al., 2013; van
der Pol et al., 2014; van der Pol et al., 2018). Since the refractive index
of a certain material correlates with the amount of light that is scat-
tered, these beads scatter more light than EV. When calibrating a
system with beads, comparable bead sizes as EV will be used but due to
their higher refractive index, they will scatter as much light as 2–3 fold
larger EV. This will result in missing the smaller population of EV and
consequently underestimating the true EV concentration (Chandler
et al., 2011). Recently, Varga and colleagues proposed hollow orga-
nosilica beads (HOB) as a suitable alternative (Varga et al., 2018). They
produced monodisperse 200 nm and 400 nm beads based on silica with
a similar refractive index as EV by mimicking the high scattering
properties of the EV membrane and the low scattering properties of the
EV lumen. They used these HOB to set nanometer size gates for EV
quantification with FCM. However, since these HOB are still mono-
disperse, while EV are heterogeneous in size, and cannot yet be pro-
duced in 100 nm size ranges, the size mode of circulating EV, optimi-
zation is still encouraged. It has been shown for instance that
measurements with FCM, NTA and TRPS resulted in larger dis-
crepancies in quantification for monodisperse liposomes compared to
EV preparations (Maas et al., 2015).
While HOB possess a favourable refractive index, they lack all other
relevant EV properties, limiting their use solely to the calibration of
light scattering technologies. Since the characterization of EV is not
limited to light scattering methods alone, but also protein-, RNA-, lipid-
and image-based methods are being used for EV characterization, it
would be convenient for a reference material to contain other relevant
EV properties. According to researchers working with EV, biochemical
composition similar to EV and stability are the two most appreciated
properties of an EV reference material (Valkonen et al., 2017). Lipo-
somes could be proposed as they are fully customizable to achieve any
EV-like properties: RNA and proteins can be incorporated, the lipid
composition can be varied and the density and refractive index can be
modulated. Liposomes have been used for the calculation of recovery
efficiencies of EV separation methods by spiking a known concentration
(based on total lipid concentration) in serum free cell culture medium
and after EV separation measuring the remaining lipid concentration
(Lane et al., 2015). Although this system gives a good representation of
the performance of EV separation methods, it cannot be used for re-
covery determination in bodily fluids as these already contain lipids
prior to the spike-in. Liposomes have also been shown to be able to
express the large extracellular loop of EV-associated tetraspanins in
their membrane (Lozano-Andrés et al., 2019). These EV-mimetics can
be used as a positive control for fluorescence triggering high resolution
FCM and the calibration of fluorescent signals after staining with a
membrane dye or with fluorescent antibodies targeting the large ex-
tracellular loop of CD9, CD63 or CD81. More complex lipid vesicles can
also be generated from whole cells. Ultrasonication of erythrocytes
results in vesicles ranging from 200 to 400 nm in size with the same
morphology, density and refractive index as erythrocyte EV, these ve-
sicles are termed NanoE (Valkonen et al., 2017). The protein compo-
sition of NanoE is different from EV and they do not contain significant
amounts of nucleic acids so they cannot be used as positive control in
protein or nucleic acid enrichment experiments, but they have been
shown to be able to function as an inter-measurement calibrator for
NTA and FCM.
Possibly the most appropriate reference material for EV are actual
EV from cell cultures or bodily fluids, or derivatives thereof, as these
contain multiple EV properties. Recently, Görgens et al. proposed EV,
containing a fusion protein of CD63 and enhanced green fluorescent
protein (EGFP), as a biological reference material for EV analysis. They
showed that these EV could be detected above the threshold with
imaging FCM based on fluorescent triggering and that these EV could be
used for the evaluation of acquisition parameters of the instrument and
EV labelling experiments. Additionally, these CD63-EGFP positive EV
can also be used to assess loss of EV during EV separation from cell
culture medium (Görgens et al., 2019). For the same purposes as the
CD63-EGFP EV, fluorescently labelled murine leukaemia viruses (MLV)
have also been proposed. Additionally, these MLV based reference
materials can be modulated to express any surface protein, making
them interesting to evaluate the labelling of cancer specific surface
markers (Chatterjee et al., 2011; Tang et al., 2019). Finally, we recently
proposed recombinant EV (rEV) as a biological reference material for
quality control, data normalization, method development and calibra-
tion of EV measurement methods. rEV were intensively characterised
and found representative of sample EV and commutable during EV
separation from bodily fluids. rEV are based on a fusion protein of the
HIV-1 major structural component gag and EGFP, which renders them
highly fluorescent and rich in EGFP mRNA. The fusion protein allows to
track rEV during separation making use of fluorescence-, protein- or
RNA based methods, by which they can be used to normalize quanti-
tative results of bodily fluid-derived EV (Geeurickx et al., 2019).
5. Assessment of cfRNA in liquid biopsies
Compared to the analysis of somatic mutations in gDNA, which only
provides information about the molecular condition of the cell of origin,
the analysis of transcribed RNA species can give complementary in-
formation concerning gene expression profiles or epigenetic alterations.
This is especially important for therapy response monitoring in cancer
patients, as therapy resistance often relies on epigenetic changes
(Esteller, 2011). In 1996 the presence of RNA in the blood of a cancer
patient was first reported, it concerned tyrosinase mRNA and its con-
centration correlated with the stage of melanoma (Stevens et al., 1996).
Following this finding, publications linking the presence of RNA in
blood to cancer remained modest up until the finding of stable mi-
croRNA (miRNA) species present in the blood of prostate cancer pa-
tients (Mitchell et al., 2008). Nowadays, cell free miRNAs (cfmiRNA)
are viewed upon as the most important RNA species for biomarker
discovery because of their higher abundance, tumor- and tissue-specific
profile, stability and their potential to alter gene expression levels upon
single stimuli (Giulia et al., 2017; Lu et al., 2005). The stability of
miRNAs in RNase-rich blood is due to complexation with proteins, li-
poproteins or platelets, or to incorporation in EV, which can protect
against RNase digestion; this is not seen for circulating mRNA, limiting
their potential as circulating cancer biomarkers (Arroyo et al., 2011;
Joosse and Pantel, 2015; Valadi et al., 2007; Vickers et al., 2011). The
exact mechanism of extracellular RNA release is not yet known for non-
vesicle associated cfRNA but, as with cfDNA, release during apoptosis
or necrosis is hypothesized.
The hematopoietic system is also the predominant source of
cfmiRNA. Hematopoietic cells can release the same miRNAs as cancer
cells, hereby hampering the identification of a true cancer biomarker
(Pritchard et al., 2012). The biological function of the same miRNA
released by a cancer cell or a hematopoietic cell however is not ne-
cessarily the same because epigenetic regulation through miRNAs is a
complex process which can occur by a single miRNA or several miRNAs
working cooperatively (Calin and Croce, 2006; Esteller, 2011). Conse-
quently, when looking for a true miRNA-based cancer biomarker it is
better to search for miRNA profiles than to focus on a single miRNA as
has been shown to be useful for hepatocellular carcinoma and breast
cancer patients diagnosis (Montani et al., 2015; Tan et al., 2019). Po-
tential cfmiRNAs as cancer biomarker are not limited to originating
from cancer cells themselves, also cells in the tumor microenvironment
release miRNAs which can promote tumor development and are thus as
important for diagnosis making (Okada et al., 2010).
Since miRNAs are the most studied population of cfRNA as potential
cancer biomarkers, we will mainly focus on this subtype when dis-
cussing the technological considerations, pre-analytical variables and
reference materials.
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5.1. Technological considerations
RNA can be isolated from bodily fluids using commercial isolation
kits based on phenol/guanidinium extraction, affinity columns or a
combination of the two. When focussing on miRNA, an additional size
exclusion step through electrophoresis can be included (Schwarzenbach
et al., 2014). Since miRNAs are associated to different compartments in
the blood (protein, lipoproteins, platelets and EV), each requiring dif-
ferent isolation procedures (centrifugation speeds, size gates and im-
mune-affinity), the subset of isolated and extracted miRNA will be de-
pendent on the used protocol. As there is no evidence present which
subset is of prior importance for biomarker discovery it could be in-
teresting to analyse the whole blood compartment or at least the whole
plasma/serum compartment for cfmiRNAs (McDonald et al., 2011).
Because miRNAs are particularly small (18–25 nt) and have spe-
cialized secondary structures, they are not only difficult to extract but
also adaptations had to be made to conventional RT-qPCR and NGS
analysis methods for increased detection (Buschmann et al., 2016; Kroh
et al., 2010; Schwarzenbach et al., 2014; T'Hoen et al., 2013). When
analysing cfmiRNA, the input sample will always be a mixture of small
RNAs (under which miRNAs) and large RNAs because RNA extraction
methods lack specificity to only extract miRNAs. As such, concentration
measurement of miRNAs is cumbersome and will always be over-
estimated by the presence of longer RNAs. Therefore, it is more con-
venient to work with fixed volumes when comparing different samples
(Kroh et al., 2010; Ono et al., 2015). Capillary electrophoresis after
RNA extraction allows to exclusively analyse miRNA, but caution is
advised as it is impossible to distinguish precursor and mature miRNA.
Cells present in blood contain high concentrations of miRNA which
can potentially influence the detection of cancer specific miRNA pro-
files. It is thus of high importance to deplete the bodily fluid completely
of whole cells and concomitantly prevent them from lysing before
analysing cfmiRNA. Similar blood collection tubes as used for cfDNA
analysis can be used for the purposes of cfmiRNA analysis. The first
drawn blood tube should be discarded, as this can contain epidermal
cell contamination by disruption of the skin with the needle (Ono et al.,
2015).
5.2. Pre-analytical variables
Due to the novelty of the cfmiRNA field no consensus exists on how
to properly treat bodily fluids and perform miRNA analysis. The in-
fluence of pre-analytical variables is being studied at a steady pace, but
not as extensively as in the cfDNA, CTC and EV field yet.
cfmiRNA can be isolated from both plasma and serum, no real
preference is set for either one of them. Although differences were
found in the miRNA profiles of both kind of bodily fluids, the total
cfRNA concentration remained similar (Kroh et al., 2010; McDonald
et al., 2011; Ono et al., 2015). When isolating cfRNA from plasma or
serum, the inflammation state of the patient and the complete blood
cell count should be monitored. This because the majority of proposed
single miRNA-based cancer biomarkers have been found to be attrib-
uted to the white blood cell count and type, so potentially only pointing
out a secondary effect of leukocytes rather than cancer cells (Pritchard
et al., 2012). Additionally, hemolysis also affects the miRNA profile in
blood by increased release of the content of red blood cells after dis-
ruption. Hemolysis should not only be checked visually but also spec-
troscopically by absorbance measurements at 414 nm. Absorbance va-
lues lower than 0.2 at this wavelength do not result in miRNA
fluctuations in the same sample (Kirschner et al., 2011). The nutritional
state of patients can also drastically impact the profiles of miRNAs in
blood, probably by an increased lipoprotein concentration, to which
miRNAs can bind to (Marzi et al., 2016; Vickers et al., 2011).
RNA extraction is a major contributor of irreproducibility, multiple
studies have conducted comparisons of different commercial RNA iso-
lation kits for the analysis of cfmiRNA and most point out that the
miRNeasy (Qiagen) results in the highest yields (Marzi et al., 2016).
RNA extraction has also been found to be variable between different
input volumes as no correlation was found with the input volume and
reported Cq values. This is due to saturation of the column by an excess
of proteins (Androvic et al., 2019). Due to its small size and low con-
centration, miRNAs can be lost during extraction by sticking to the
plastic. This can be prevented by addition of carrier tRNA or glycogen,
the latter has been found to be better because an excess of tRNA can
potentially influence the analysis (Androvic et al., 2019). Variability
during RNA extraction can be reduced by working with fixed volumes,
not only the input volumes, but also when separating the aqueous phase
when using phenol/guanidinium-based extractions (Marzi et al., 2016).
Expression values of miRNAs in plasma and serum were found
stable after multiple freeze thaw cycles at −80 °C, although storage at
4 °C for up to 72 h did not seem to impact the expression profiles (Kroh
et al., 2010).
RNA expression is subjected to multiple stimuli and can therefore
easily vary between samples, even when there is no causality.
Therefore, miRNA profile normalization should be performed with
good internal reference genes, preferably found to be stable in all
conditions of the experiment (Bustin et al., 2009). Up until now, no
good reference controls have been found but miR-16, miR-30b and miR-
142-3p are often used as internal normalizers, although the first one has
been found to be influenced by hemolysis (Ono et al., 2015; Pritchard
et al., 2012; Schaefer et al., 2010). Another way of normalizing for
miRNA expression is the use of mean miRNA expression values, which
has been found to be relatively invariable throughout multiple samples.
When looking for appropriate reference genes, the stability thereof
should be compared to the mean miRNA expression value (Mestdagh
et al., 2009).
When using the same input samples, reproducibility, specificity,
sensitivity and accuracy can still vary between miRNA expression
platforms, even when these platforms are based on the same technol-
ogies. qPCR-based platforms for instance have been found to have a
higher sensitivity and accuracy when it comes to low input samples.
This suggests that the miRNA expression platform should be chosen
based on the experimental settings (Mestdagh et al., 2014).
5.3. Reference materials for cfRNA
To partially correct for errors during extraction, an often-used
method is to spike non-homologous miRNA molecules, for instance C.
elegans miRNAs, in the sample undergoing extraction. This spike-in
should not be performed in the untreated bodily fluid, since they often
contain a high concentration of RNases, but after adding denaturation
buffers. It is especially important that these spike-ins contain 5’ term-
inal phosphate to allow them to be incorporated into miRNA libraries
for NGS. These non-homologous miRNA sequences can also be spiked
after extraction and prior to reverse transcription and PCR to check for
the presence of PCR inhibitors, as explained above for cfDNA reference
materials. Regarding this, an effort to standardize the miRNA workflow
was recently published where they made use of 3 extraction spike-ins, 2
RT spike-ins and 3 endogenous miRNA to assess the performance of
miRNA extraction, the presence of PCR inhibitors and the contamina-
tion of cellular miRNA originating from erythrocytes (Androvic et al.,
2019).
The field of cfRNA is still in its infancies and RNA expression ana-
lysis methods, especially sequencing methods, are still being optimized.
To optimize these methods, well characterised reference materials are
strongly needed that mimic true RNA species in physiological con-
centration ranges. To address this need, the External RNA Control
Consortium (ERCC) have put in remarkable effort to develop a spike-in
control to optimize the RNA expression field (Baker et al., 2005; Cronin
et al., 2004). This ERCC reference material consist of 96 polyadenylated
transcripts that mimic natural eukaryotic mRNAs but are not identical
(less than 0.01% of reads mapped to the human genome). They are
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designed to have a wide range of lengths (250–2000 nucleotides) and
GC-contents (5–51%) and can be spiked into RNA samples before li-
brary preparation at various concentrations to assess the RNA sequen-
cing workflow. Standard curves can be achieved with the ERCC spikes,
demonstrating a linear quantification over 6 orders of magnitude,
proving that they can also be used to normalize RNA sequencing data
(Jiang et al., 2011). However, caution must be given when using these
ERCC spikes for normalization since it was demonstrated that the read
counts are affected by the biological factors studied (Risso et al., 2014).
More recently, a related spike-in material was developed to assess
the small-RNA sequencing workflow. Locati and colleagues developed
two different spike-in sets. Size-range quality controls (SRQC) set which
can be used to assess size selection bias of NGS, as the library pre-
paration makes use of size exclusion steps. SRQC consist of 11
Table 1
Initiatives concerning the standardization of liquid biopsy research.
Initiative Description Aims/Projects
EURAMET (EURopean Association of
national METrology institutes)
(https://www.euramet.org)
Leading metrology organisation of Europe that coordinates the
cooperation of national metrology institutes in Europe in fields
such as research in metrology and international recognition of
national measurement standards.
• European Metrology Programme for Innovation and Research
(EMPIR) calls for funding for standardization efforts (fi. SRT-
h19).• METVES (metrological characterization of micro-vesicles from
body fluids) joint research project.
SPIDIA4P
(https://www.spidia.eu)
Consortium of 19 experienced academic, industrial and
governmental partners focussed on international standardisation
for in vitro diagnostics.
• Development of pre-analytical CEN and ISO standard
documents as well as corresponding EQA schemes and
implementation tools for potential biomarkers.
JIMB (Joint Initiative for Metrology in
Biology)
(https://jimb.stanford.edu)
Consortium of Stanford researchers and industrial partners with
the goal to advance metrology in genomics and synthetic
biology, hosted by NIST.
• Genome in a bottle (GIAB) initiative: development of reference
standards, -methods and -data to bring whole genome
sequencing to clinical practice.• External RNA controls consortium (ERCC): development of RNA
spike-in controls and standard analytical methods.
NIBSC (National Institute for Biological
Standards and Controls)
(https://nibsc.org)
World leading organisation in the characterization,
standardization and control of biological medicines and
biomarkers.
• Distribution of WHO-approved standards and reference
materials for both cancer genomes and ctDNA.
JCTLM (Joint Committee for
Traceability in Laboratory
Medicine)
(https://www.bipm.org/jctlm)
International consortium for the promotion of global
standardization of clinical laboratory tests.
• Provides information on reference materials, measurement
methods and services available.• Global database of higher order reference materials, measurement
methods and services.
(GeT-RM)
(Genetic Testing Reference
Materials Coordination Program)
(https://www.cdc.gov/clia/get-
rm/index.html)
Program of the US Clinical Laboratory Improvement
Amendments (CLIA) as part of the Centers for Disease Control
and Prevention (CDC) institute to improve the availability of
appropriate reference materials for genetic testing.
• Curated list of available standardized-, certified-, FDA-cleared-
or CE-marked reference materials.• Guidance for the generation and validation of standardized
reference materials.
BBRB (Biorepository and Biospecimens
Research Branch)
(https://biospecimens.cancer.gov/
default.asp)
Working group of the Cancer Diagnosis program of the National
Cancer Institute (NCI) concerning biorepository standards for the
facilitation of Biospecimen Science studies.
• Biospecimen pre-analytical variables program (BPV):
systematic assessment of the effects of pre-analytical variables
on the molecular profile of biospecimens.• Biospecimen research database: contains peer-reviewed articles
and SOPs in the human biospecimen field.
EDRN (Early Detection Research
Network)
(https://edrn.nci.nih.gov)
Initiative of the NCI to accelerate the translation of biomarker
information into clinical applications by bringing together
multiple institutions working on cancer detection.
• Providing funding for the standardization of liquid biopsy
research.• Collaboration with NIST for the development of ctDNA reference
materials.
ERCC (Extracellular RNA
Communication Consortium)
(https://exrna.org)
Research consortium funded by the NIH common fund with the
goal to explore the new field of intercellular RNA
communication.
• exRNA atlas: Data repository containing all exRNA reported for
each bodily fluid together with the used protocol.• exRNA portal: Central access point for exRNA resources including
SOP, standards and reagents.
CBC (AACR-FDA-NCI Cancer Biomarker
Collaborative)
Cancer stakeholder-driven collaboration with the aim to
accelerate the FDA’s Critical Path Initiative.
• CBC consensus report that identifies 8 areas of concern for
biomarker development and provides strategies for the
acceleration of translation to the clinic (Khleif et al., 2010).
GSC (Genomics Standards Consortium)
(https://press3.mcs.anl.gov/gensc)
Open membership research consortium aiming at making
genomic data discoverable and reproducible.
• Providing community specific standards and minimal
information statements for the correct execution of experiments
and reporting of data.
Cancer-ID
(https://www.cancer-id.eu)
European public-private partnership aiming at establishing SOPs
and clinical validation of blood-based biomarkers.
• Establishment of the European Liquid Biopsy Society (ELBS)
aiming at bringing together European research groups,
disseminating knowledge and providing training.• Publishing of thorough relevant reviews and standardized
workflows for liquid biopsy research (https://www.cancer-id.eu/
news/scientific-publications).
BloodPAC (Blood Profiling Atlas in
Cancer)
(https://www.bloodpac.org)
US research consortium existing of partners from academia,
private foundations, industry and the government aiming to
accelerate the progress of the liquid biopsy field for an improved
understanding of patient disease.
• Development of minimum technical data elements (MTDEs)
data set containing relevant information of historic liquid
biopsy projects needed to develop pre-analytical SOPs for assay
development.
Biomarker consortium
(https://fnih.org/what-we-do/
biomarkers-consortium)
US public-private biomedical research partnership managed by
the Foundation for the National Institutes of Health (FNIH)
aiming for the development of and seeking regulatory approval
for biomarkers of any disease.
• Identification and validation of ctDNA Quality control materials
(project).
EV flowcytometry working group
(http://www.evflowcytometry.org)
Working group of flow cytometry experts from the International
Society for Extracellular Vesicles (ISEV), International Society
for the Advancement of Science (ISAC), and International
Society on Thrombosis and Hemostasis (ISTH) for the
establishment of guidelines for best practices in EV flow
cytometry.
• MIFlowCytEV: List of minimum information about a Flow
Cytometry Experiment when working on EV.
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synthetically synthesized, single-stranded 5′-phosphorylated RNA se-
quences of increasing length (10–70 nucleotides). External reference for
data normalization (ERDN) set which consist of 19 single-stranded 5′-
phosphorylated RNA sequences of 25 nucleotides that cover the phy-
siological expression range of small RNAs in blood. This spike-in set can
be used to normalize small RNA sequencing data based on the total
input prior to analysis (Locati et al., 2015).
As there is still much to optimize in the RNA sequencing workflow,
most of the RNA reference materials being developed are concerning
this. Due to the limited scope of this review we will not go further into
detail while providing further references for review (Buschmann et al.,
2016; Hardwick et al., 2017, 2016; Munro et al., 2014; Paul et al., 2016;
Risso et al., 2014). Because of this high need to standardize the RNA
sequencing workflow, no efforts were conducted to develop analytical
reference materials yet. The question remains however whether this
will ever take place because miRNA profiles in a complex bodily fluid
are difficult to mimic compared to single mutation detection or detec-
tion of mutated cells.
6. Measures for increased reproducibility in the liquid biopsy field
Liquid biopsies hold great potential for future diagnosis, prognosis
and therapy monitoring of cancer patients. However, only three liquid
biopsy tests are FDA approved, two cfDNA- (cobas EGFR Mutation Test
v2 and Epi proColon) and a CTC-based test (CellSearch). The reason for
this low FDA approval rate is the general low level of reproducibility in
pre-clinical research. This lack of reproducibility is particularly higher
for cancer research compared to other research fields, supposedly due
to the higher urgency for finding solutions in oncology (Begley and
Ellis, 2012). With a high concentration of researchers working on
cancer detection through analysing hard-to-isolate biomarkers from
complex bodily fluids, the field is over flooded with lab-specific pro-
tocols for isolation and analysis. This was illustrated by a meta-analysis
of EV research where 1226 EV related articles from 2010 to 2015 were
thoroughly analysed and found reporting 190 unique EV isolation
methods, which resulted in 1038 unique protocols through adaptations
of previous methods. This, together with incomplete reporting of the
experimental set-up, hampers unambiguous interpretation or replica-
tion of experiments (Van Deun et al., 2017).
Since the increased attention for the lack of reproducibility in pre-
clinical cancer research, the global biological standard institute (GBSI)
published the case for standards in which they assessed the quality of
research, identified areas of concern, and proposed recommendations
for improvements (Freedman and Inglese, 2014; “The Case for
Standards in Life Science Research: Seizing Opportunities at a Time of
Critical Need,”). With this publication GBSI aimed at raising awareness
for standards among all stakeholders of life science research and its
progress, and stimulating them to engage in community efforts to create
consensus standards in life science research. Standards imply both re-
ference materials and consensus documents generated by professional
communities. The latter can range from simple SOP to more complex
standards for data analysis or accurate reporting guidelines. Such
consensus documents are important for the correct execution of ex-
periments, interpretation of results and for the findability of published
results (Freedman et al., 2017). Such standards should not directly
come from standards developing organisations (SDO), such as ISO
(International Organization for Standardization) or CEN (European
Committee for Standardization) (de jure standards) but should be
proposed by community efforts after lengthy discussions with all sta-
keholders in the field, including researchers, publishers and funders (de
facto standards). The most important community efforts for standar-
disation of the liquid biopsy field and their impact are summarized in
Table 1. Important for the generation of community standards is to
include as much stakeholders as possible and prevent the generation of
multiple standards for the same topic. This can result in fragmentation
of community efforts and prevent the implementation of real
community standards in practice (Cargill, 2011; Sansone and Rocca-
Serra, 2012). Recently, an informative and educational resource tool
was launched, FAIRsharing, that describes and interlinks community
standards, databases, repositories and data policies in one searchable
database (Sansone et al., 2019). With this database researchers, funders
and publishers can lookup resources to identify standards, databases or
repositories that exist for their data and discipline with the goal to re-
spectively improve the success rate of their experiments, increase the
impact of the funded work and reduce irreproducible data being pub-
lished by enforcing topic-specific standards.
Reference materials can also be developed by community efforts
followed by commercialization. ctDNA reference materials provided by
SeraCare and Horizon were developed in collaboration with respec-
tively the National Institute for Standards and Technology (NIST) –
Early Detection Research Network (EDRN) collaborative (NIST-ERDN)
in the US and LGC limited in the UK. Such reference materials can be
trusted to represent the subject of interest, as it is a result of broad
community discussions, proficiency testing and external quality as-
sessment (EQA) (Haselmann et al., 2018). However, reference materials
can also be commercially provided by private companies without par-
ticipation of community efforts. These reference materials should be
tested appropriately because they are mostly not subjected to rigorous
proficiency testing and EQA. At its best, a reference material must be
fully traceable and the producer or reference material itself should be
certified by an SDO. In the case of ISO these producers or materials
should follow ISO 30:2015, ISO 31:2015, ISO 33:2015, ISO 35:2015,
ISO 17034:2016 guides. However, traceability is difficult to achieve for
biological reference materials. A reference material that adheres to all
these criteria is available for chronic myelogenous leukaemia and
Philadelphia chromosome-positive acute lymphoblastic leukaemia and
is approved by the WHO (White et al., 2010).
7. Concluding remarks
Liquid biopsies hold much promise for improving early cancer de-
tection and monitoring therapy response, consequently improving
overall patient survival. However, liquid biopsy research projects rarely
find their way to clinical application because of a lack of reproducibility
(Merker et al., 2018; Watts, 2018). Community established SOP and
reference materials should be developed to avoid the influence of pre-
analytical variables and increase reproducibility of measurement
methods. In the last decade, multiple community efforts focussing on
the standardization of the liquid biopsy field were initiated and con-
tributed as such. The rise of these community efforts could mean the
turning point of irreproducible pre-clinical studies and hopefully the
implementation of liquid biopsy tests in the clinic.
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